眼感染症治療の世界市場:結膜炎、角膜炎、眼瞼炎

Technavioが発行した調査報告書(IRTNTR32102)
◆英語タイトル:Eye Infections Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32102
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月
◆ページ数:149
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、眼感染症治療の世界市場について調べ、眼感染症治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、眼感染症治療の市場規模をセグメンテーション別(種類別(結膜炎、角膜炎、眼瞼炎、その他の眼感染症)、)と地域別(グローバル)に分けて算出しました。Technavio社は眼感染症治療の世界市場規模が2019-2023期間中に年平均3%成長すると予測しています。
・サマリー
・レポートの範囲
・眼感染症治療の市場状況
・眼感染症治療の市場規模
・眼感染症治療の市場予測
・眼感染症治療の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(結膜炎、角膜炎、眼瞼炎、その他の眼感染症)
・眼感染症治療の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Eye Infections Therapeutics Market: About this market

Technavio’s eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.

Global Eye Infections Therapeutics Market: Overview

Rising geriatric population

The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.

Growing adoption of generics

The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global eye infections therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global eye infections therapeutics market is highly fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.

Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Conjunctivitis – Market size and forecast 2018-2023

Keratitis – Market size and forecast 2018-2023

Blepharitis – Market size and forecast 2018-2023

Other eye infections – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Rising number of government initiatives

Growing adoption of generics

Saturation in the pipeline landscape

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Akorn Inc.

Allergan Plc

Bausch Health Companies Inc.

Bayer AG

Daiichi Sankyo Co. Ltd.

GlaxoSmithKline Plc

Novartis AG

Pfizer Inc.

Sanofi

Santen Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Conjunctivitis – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Conjunctivitis – Year-over-year growth 2019-2023 (%)

Exhibit 22: Keratitis – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Keratitis – Year-over-year growth 2019-2023 (%)

Exhibit 24: Blepharitis – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Blepharitis – Year-over-year growth 2019-2023 (%)

Exhibit 26: Other eye infections – Market size and forecast 2018-2023 ($ millions)

Exhibit 27: Other eye infections – Year-over-year growth 2019-2023 (%)

Exhibit 28: Market opportunity by type

Exhibit 29: Customer landscape

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Vendor landscape

Exhibit 48: Landscape disruption

Exhibit 49: Vendors covered

Exhibit 50: Vendor classification

Exhibit 51: Market positioning of vendors

Exhibit 52: Akorn Inc. – Vendor overview

Exhibit 53: Akorn Inc. – Business segments

Exhibit 54: Akorn Inc. – Organizational developments

Exhibit 55: Akorn Inc. – Segment focus

Exhibit 56: Akorn Inc. – Key offerings

Exhibit 57: Akorn Inc. – Key customers

Exhibit 58: Allergan Plc – Vendor overview

Exhibit 59: Allergan Plc – Product segments

Exhibit 60: Allergan Plc – Organizational developments

Exhibit 61: Allergan Plc – Segment focus

Exhibit 62: Allergan Plc – Key offerings

Exhibit 63: Allergan Plc – Key customers

Exhibit 64: Bausch Health Companies Inc. – Vendor overview

Exhibit 65: Bausch Health Companies Inc. – Business segments

Exhibit 66: Bausch Health Companies Inc. – Organizational developments

Exhibit 67: Bausch Health Companies Inc. – Geographic focus

Exhibit 68: Bausch Health Companies Inc. – Segment focus

Exhibit 69: Bausch Health Companies Inc. – Key offerings

Exhibit 70: Bausch Health Companies Inc. – Key customers

Exhibit 71: Bayer AG – Vendor overview

Exhibit 72: Bayer AG – Business segments

Exhibit 73: Bayer AG – Organizational developments

Exhibit 74: Bayer AG – Geographic focus

Exhibit 75: Bayer AG – Segment focus

Exhibit 76: Bayer AG – Key offerings

Exhibit 77: Bayer AG – Key customers

Exhibit 78: Daiichi Sankyo Co. Ltd. – Vendor overview

Exhibit 79: Daiichi Sankyo Co. Ltd. – Business segments

Exhibit 80: Daiichi Sankyo Co. Ltd. – Organizational developments

Exhibit 81: Daiichi Sankyo Co. Ltd. – Geographic focus

Exhibit 82: Daiichi Sankyo Co. Ltd. – Key offerings

Exhibit 83: Daiichi Sankyo Co. Ltd. – Key customers

Exhibit 84: GlaxoSmithKline Plc – Vendor overview

Exhibit 85: GlaxoSmithKline Plc – Business segments

Exhibit 86: GlaxoSmithKline Plc – Organizational developments

Exhibit 87: GlaxoSmithKline Plc – Geographic focus

Exhibit 88: GlaxoSmithKline Plc – Segment focus

Exhibit 89: GlaxoSmithKline Plc – Key offerings

Exhibit 90: GlaxoSmithKline Plc – Key customers

Exhibit 91: Novartis AG – Vendor overview

Exhibit 92: Novartis AG – Business segments

Exhibit 93: Novartis AG – Organizational developments

Exhibit 94: Novartis AG – Geographic focus

Exhibit 95: Novartis AG – Segment focus

Exhibit 96: Novartis AG – Key offerings

Exhibit 97: Novartis AG – Key customers

Exhibit 98: Pfizer Inc. – Vendor overview

Exhibit 99: Pfizer Inc. – Business segments

Exhibit 100: Pfizer Inc. – Organizational developments

Exhibit 101: Pfizer Inc. – Geographic focus

Exhibit 102: Pfizer Inc. – Segment focus

Exhibit 103: Pfizer Inc. – Key offerings

Exhibit 104: Pfizer Inc. – Key customers

Exhibit 105: Sanofi – Vendor overview

Exhibit 106: Sanofi – Business segment

Exhibit 107: Sanofi – Organizational developments

Exhibit 108: Sanofi – Geographic focus

Exhibit 109: Sanofi – Segment focus

Exhibit 110: Sanofi – Key offerings

Exhibit 111: Sanofi – Key customers

Exhibit 112: Santen Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 113: Santen Pharmaceutical Co. Ltd. – Business segments

Exhibit 114: Santen Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 115: Santen Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 116: Santen Pharmaceutical Co. Ltd. – Segment focus

Exhibit 117: Santen Pharmaceutical Co. Ltd. – Key offerings

Exhibit 118: Santen Pharmaceutical Co. Ltd. – Key customers

Exhibit 119: Validation techniques employed for market sizing

Exhibit 120: Definition of market positioning of vendors



【掲載企業】

Akorn Inc.
Allergan Plc
Bausch Health Companies, Inc.
Bayer AG
Daiichi Sankyo Co. Ltd.
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.
Sanofi
Santen Pharmaceutical Co. Ltd.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 眼感染症治療の世界市場:結膜炎、角膜炎、眼瞼炎(Eye Infections Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆